Hypermethylation of the Wilms' tumor suppressor gene CpG island in human breast carcinomas

Breast Cancer Research and Treatment

Volumn 56, Issue 1, 1999, Pages 35-43

  Laux, Douglas E ^a   Curran, Edward M ^a   Welshons, Wade V ^a   Lubahn, Dennis B ^a   Huang, Tim H M ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

Breast cancer; CpG island; DNA hypermethylation; Wilms' tumor suppressor gene

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA; MESSENGER RNA;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; NEPHROBLASTOMA; PRIORITY JOURNAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CPG ISLANDS; EXONS; FEMALE; GENES, WILMS TUMOR; HUMANS; METHYLATION; PROMOTER REGIONS (GENETICS); TUMOR CELLS, CULTURED;

EID: 0032868411     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006222803788     Document Type: Article

References (33)

1. Ottaviano YL, Issa J-P, Parl FF, Smith HS, Baylin SB: Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 54: 2552-2555, 1994
2. Baylin SB, Makos M, Wu JJ, Yen RWC, de Bustros A, Vertino P, Nelkin BD: Abnormal patterns of DNA methylation in human neoplasia: potential consequences for tumor progression. Cancer Cells 3: 383-390, 1991
3. Jones PA: DNA methylation errors and cancer. Cancer Res 56: 2463-2467, 1996
4. Adams RLP, Burdon RH: Molecular Biology of DNA Methylation. Springer-Verlag, New York, 1985
5. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, Dryja TP: Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet 48: 880-888, 1991
6. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linchan WM: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91: 9700-9704, 1994
7. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525-4530, 1995
8. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Turnout JM, Jones PA: Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55: 4531-4535, 1995
9. Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S: Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 92: 7416-7419, 1991
10. Ferguson AT, Lapidus RG, Baylin SB, Davidson NE: Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res 55: 2279-2283, 1995
11. Lapidus RG, Ferguson AT, Ottaviano YL, Parl FF, Smith HS, Weitzman SA, Baylin SB, Issa J-PJ, Davidson NE: Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res 2: 805-810, 1996
12. Huang TH-M, Laux DE, Hamlin BC, Tran P, Tran H, Lubahn DB: Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique. Cancer Res 57: 1030-1034, 1997
13. Craig JM, Bickmore WA: The distribution of CpG islands in mammalian chromosomes [published erratum appears in Nat Genet 7: 551, 1994]. Nat Genet 7: 376-382, 1994
14. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH, Jones C, Housman DE: Isolation arid characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60: 509-520, 1990
15. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GAP: Homozygous deletion in Wilms' tumours of a zinc finger gene identified by chromosome jumping. Nature 343: 774-778, 1990
16. Rauscher FJ 3rd: The WT1 Wilms' tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor FASEB 7: 896-903, 1993
17. Pritchard-Jones K, Fleming S, Davidson D, Bickmore W, Porteous D, Gosden C, Bard J, Buckler A, Pelletier J, Housman D, Van Heyningen V, Hastie N: The candidate Wilms' tumour gene is involved in genitourinary development. Nature 346: 194-197, 1990
18. Menssen HD, Renkl HJ, Rodeck U, Maurer J, Notter M, Schwartz S, Reinhardt R, Thiel E: Presence of Wilms' tumor gene (WT1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 9: 1060-1067, 1995
19. Rodeck U, Bossler A, Kari C, Humphreys CW, Gyorfi T, Maurer J, Thiel E, Menssen HD: Impression of the WT1 Wilms' tumor gene by normal and malignant human melanocytes. Inter J Cancer 59: 78-82, 1994
20. Amin KM, Litzky LA, Smythe WR, Mooney AM, Morris JM, Mews DJ, Pass III, Kari C, Rodeck U, Rauscher FJ 3rd, Kaiser LR, Albelda SM: Wilms' tumor I susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Path 146: 344-356, 1995
21. Bruening W, Gros P, Sato T, Stanimir J, Nakamura Y, Housman D, Pelletier J: Analysis of the 11p13 Wilms' tumor suppressor gene (WT1) in ovarian tumors. Cancer Invest 11: 393-399, 1993
22. Silberstein GB, Van Horn K, Strickland P, Roberts CTJ, Daniel CW: Altered expression of the WT1 Wilms' tumor suppressor gene in human breast cancer. Proc Natl Acad Sci USA 94: 8132-8137, 1997
23. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, Kita K, Hiraoka A, Masaoka T, Nasu K, Kyo T, Dohy H, Nakauchi J, Ishidate T, Akiyama T, Kishimoto T: WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84: 3071-3079 1994
24. Huang TH, Hejtmancik JF, Edwards A, Pettigrew AL, Herrera CA, Hammond HA, Caskey CT, Zoghbi HY, Ledbetter DH: Linkage of the gene for an X-linked mental retardation disorder to a hypervariable (AGAT)n repeat motif within the human hypoxanthine phasphoribosyltransferase (HPRT) locus (Xq26). Am J Hum Genet 49: 1312-1319, 1991
25. Cross SH, Charlton JA, Nan X, Bird AP: Purification of CpG islands using a methylated DNA binding column. Nat Genet 6: 236-244, 1994
26. Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman DE: Alternative splicing and genomic structure of the Wilms' tumor gene WT1. Proc Natl Acad Sci USA 88: 9618-9622, 1991
27. Paik S: Expression of IGF-I and IGF-II mRNA in breast tissue. Breast Cancer Res Treat 22: 31-38, 1992
28. Coombes RC, Barrett-Lee P, Luqmani Y: Growth factor expression in breast tissue. J Steroid Biochem Mol Biol 37: 833-836, 1990
29. Silberstein GB, Flanders KC, Roberts AR, Daniel CW: Regulation of mammary morphogenesis: evidence for extracellular matrix-mediated inhibition of ductal budding by transforming growth factor-beta 1. Dev Biol 152: 354-362, 1992
30. Eccles MR, Grubb G, Ogawa O, Szeto J, Reeve AE: Cloning of novel Wilms' tumor gene (WT1) cDNAs; evidence for antisense transcription of WT1. Oncogene 9: 2059-2063, 1994
31. Royer-Pokora B, Schneider S: Wilms' tumor-specific methylation pattern in 11p13 detected by PFGE. Genes, Chromosomes and Cancer 5: 132-140, 1992
32. Hiltunen MO, Koistinaho J, Alhonen L, Myohanen S, Marin S, Kosma VM, Paakkonen M, Janne J: Hypermethylation of the WT1 and calcitonin gene promoter regions al chromosome 11p in human colorectal cancer. Br J Cancer 76: 1124-1130, 1997
33. American Joint Committee on Cancer: Manual for staging of cancer. J.B. Lippincott Co., Philadelphia, 1989, pp 93-99